NRC Health (National Research Corporation) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. NRC Health provides analytics and insights to healthcare organizations, primarily through renewable subscription services. Financial statements are unaudited.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $35.3 million | $36.5 million | Down 3% |
| Operating income | $8.8 million | $9.0 million | Down 3% |
| Operating margin | 25% reported | 25% reported | Unchanged |
| Net income | $6.4 million | $7.0 million | Down 9% |
| Diluted EPS | $0.27 | $0.28 | Down $0.01 |
| Cash from operating activities | $12.0 million | $7.8 million | Up 55% |
| Recurring contract value | $139.5 million | $146.7 million | Down 5% |
Revenue was lower mainly because U.S. recurring revenue from existing clients declined by $1.1 million; half of that decrease came from non-core solutions. Subscription services contributed $33.3 million of revenue. Direct expenses and SG&A declined 3% and 5%, respectively, while depreciation and amortization increased 4%. Higher interest expense and lower interest income drove total other expense to $0.6 million, versus $0.005 million in Q1 2023. The effective tax rate was 22%, compared with 23%.
Cash, liquidity and debt
- Cash and equivalents were $1.7 million at March 31, down from $6.7 million at year-end. Operating cash flow was $12.0 million; capital expenditures were $4.1 million.
- Working capital was negative $28.8 million, compared with negative $11.8 million at December 31, 2023. Management attributes part of the working-capital profile to deferred revenue from advance billings and says available liquidity and operating cash flows should meet projected needs for the foreseeable future.
- Notes payable were approximately $35.1 million, and the revolving credit line had $7.0 million outstanding. The company reported $23.0 million of remaining revolver availability and $56.0 million available under the delayed-draw term facility, which is restricted to permitted acquisitions or share repurchases.
- The term loan bears fixed interest at 5%; delayed-draw and revolver borrowings bear floating interest at SOFR plus 235 basis points (7.67% at quarter-end). The revolver matures May 2025; the delayed-draw loan has a $10.2 million balloon due May 2027.
- The company was in compliance with its financial covenants at quarter-end. It must maintain a minimum 1.10x fixed-charge coverage ratio and cash-flow leverage of no more than 3.00x.
Capital allocation and outlook
NRC Health repurchased 366,454 shares for $15.0 million in Q1 at an average $40.93 per share, and paid $2.9 million in dividends. The company declared another $2.9 million dividend, paid in April. It expects $8.4 million of headquarters renovation costs in 2024 and $1.4 million in 2025, funded through operating cash flow and revolver borrowings.
No specific revenue or earnings guidance is provided. Management cited insufficient new-contract growth to replace losses as the primary reason recurring contract value declined, while client retention remained fairly consistent. It expects direct expenses to rise as service and technology functions are restructured and investments are made in client support and AI-enabled solutions. SG&A is also expected to increase with new executive positions and sales-team restructuring.
Risks, contingencies and unusual items
- Key risks include contract non-renewals or reduced client spending, competitive and pricing pressure, healthcare-industry consolidation, economic conditions, personnel retention, technology or platform failures, and cybersecurity incidents.
- Debt is secured by substantially all company assets and includes restrictions on additional debt, acquisitions, dividends and share repurchases, subject to specified exceptions.
- Management does not expect pending ordinary-course claims and litigation to materially affect financial position, results or liquidity. The filing notes that legal matters can nevertheless entail costs and reputational effects.
- Q1 share repurchases and renovation investment reduced liquidity; the company also borrowed on its revolver to fund repurchases. Cash provided by operations benefited from working-capital timing, so the increase should not be read as solely earnings-driven.
- Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported during the quarter.
Investor verification priorities
- Track recurring contract value, renewals, new-contract additions and client losses, including performance of non-core solutions.
- Assess whether expected expense increases and AI/service investments improve growth and margins after the reported revenue decline.
- Monitor cash generation, the working-capital deficit, renovation spending and remaining liquidity, including revolver use and the restricted delayed-draw availability.
- Verify covenant headroom, borrowing costs and the May 2025 revolver maturity, alongside continued dividends and repurchases.
- Review future disclosures for changes in litigation, uncertain tax positions or other contingencies; the filing does not quantify a material expected loss from pending litigation.